A US federal judge ruled that using patients' stem cells for medical treatments is not under FDA jurisdiction, potentially speeding up development of stem cell-based hair loss therapies. Some users are optimistic about increased research and development, while others express skepticism about the ruling's impact on safety and efficacy standards.
A treatment containing Wnt and Follistatin was found to be safe and effective for hair regrowth in a Phase 1 clinical trial. Specific treatments discussed include Minoxidil, Finasteride, and RU58841.
RU58841 is a controversial hair loss treatment with mixed reviews; some users report success, often in combination with other treatments like finasteride or minoxidil, while others experience side effects like chest pain. The treatment's discontinuation is speculated to be due to patent expiration and lack of profitability, despite some users continuing to use it as part of a broader regimen.
A user shared their successful hair loss treatment using RU58841, topical minoxidil, and microneedling, noting significant improvement over three months. They chose RU58841 over finasteride due to personal preference and reported no side effects, while others discussed their experiences with different treatments and supplements.
A dermatologist recommended PRP (Platelet Rich Plasma) and GFC (Growth Factor Concentrate) for pattern baldness, but online sources suggest they may not be effective. The user is seeking opinions on these treatments.
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
The conversation is about using alfatradiol as a hair loss treatment. The user is considering adding it to their regimen because it is safe, mild, and easily available in Europe.
Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.
RU58841 caused severe side effects like heart palpitations and shortness of breath, leading the user to stop using it. Minoxidil and finasteride were effective without side effects, while RU58841's safety and effectiveness remain uncertain.
A 23-year-old is experiencing hair loss and is using a regimen including topical Minoxidil, finasteride, spironolactone, and Estradiol gel as part of hormone replacement therapy (HRT). They are hopeful for hair regrowth and are considering using a micro needler, with others suggesting that their current treatment could lead to significant improvement.
The user stopped using finasteride due to side effects and switched to RU58841, which seems to be working for hair regrowth. They are considering RU58841 and minoxidil as long-term treatments, while others discuss the safety and effectiveness of these options.
The user experienced significant hair regrowth and improved scalp condition using GHK-Cu peptide, minoxidil, and finasteride over 15 months, with GHK-Cu alone showing noticeable results before adding the other treatments. They reported some side effects like scalp irritation and sleep disturbances but found the combination of treatments satisfactory and confidence-boosting.
The user is using RU58841, Revivogen, Regenepure ketoconazole shampoo, and plans to use a stimufield cap to address hair loss. They aim to avoid finasteride and minoxidil while hoping to stop hair loss and regrow hair.
RU58841 has been used by a person for 5 years, effectively regrowing and maintaining hair without noticeable side effects, though there are concerns about potential long-term risks. The user initially tried finasteride but did not achieve the desired results.
Hair regrowth is possible with a combination of finasteride, minoxidil, and estrogen, though it may take time to see results. Users suggest using minoxidil foam and considering additional treatments like microneedling, while also exploring options like wigs or hair systems in the meantime.
Amplifica has not provided updates on SCUBE3 and AMP-303, raising concerns about their trial outcomes. Users also mention other treatments like Minoxidil, finasteride, RU58841, PP405, and ET-03.
A transgender woman experienced significant hair regrowth after 18 months of hormone replacement therapy (HRT) with estrogen and bicalutamide. The discussion notes HRT's effectiveness for hair regrowth but warns against its use for cisgender men due to feminizing effects.
The user has scheduled a hair transplant after stabilizing hair loss with finasteride and minoxidil, considering additional dermarolling. They are advised to use 2500-3000 grafts conservatively for temple filling without lowering the hairline too much.
Saw palmetto extract, rosemary oil, microneedling, fluconazole shampoo, and red light therapy helped improve hair thickness and reverse hair loss without using minoxidil or finasteride. The user experienced significant hair regrowth and no longer feels insecure about hair loss.
The conversation discusses using alfatradiol, a weaker estrogen, as a treatment for hair loss, with some users sharing their experiences and challenges in obtaining it. One user mentions using a topical solution containing alfatradiol, cetricin, caffeine, and melatonin, noting no significant hair growth but stabilization.
RU58841 is absorbed systemically in humans, contradicting claims it stays local, but no harm is proven. Alternatives like CB-03-01 or KX-826, especially with finasteride, are suggested for safety.
The conversation is about hair loss treatments, specifically discussing RU58841, with concerns about its safety and lack of research. Alternatives like finasteride, dutasteride, and minoxidil are mentioned, with some users sharing personal experiences and side effects.
Hims reactivated a subscription without consent, leading to unauthorized charges for Finasteride and Minoxidil products, and refused to issue a refund until a bank dispute was filed. Users discussed alternative, cheaper sources for these treatments and shared similar negative experiences with Hims.
Follicium XR™ is a topical treatment for hair loss containing RU58841, AHK-Cu, GHK-Cu Peptide, caffeine, D-Biotin, methylene blue, keratin, and spermidine. RU58841 is considered the most effective ingredient, but concerns exist about its stability in water.
A user shared their journey from balding to using a hair system, expressing satisfaction with the results despite the costs. They mentioned trying finasteride but stopped due to side effects, and now enjoy increased attention from women with the hair system.
A user is seeking a hair loss formula containing Redensyl and Capixyl without caffeine, Saw Palmetto, or other herbs. They want recommendations for such a product.
The conversation is about a user interested in participating in hair cloning clinical trials due to their fine hair and previous positive experience with clinical trials. They are seeking information on how to volunteer for such trials.
The conversation is about using alfatradiol (17α-estradiol) as a hair loss treatment. The user is considering adding it to their regimen due to its safety and availability.
The user shared progress pictures after 2 months of minoxidil, 1.5 months of microneedling, 1 month of RU58841, and 10 days of topical minoxidil and finasteride. They discussed their hair loss treatment regimen and results.